This presentation was recorded live at the 2016 IVC and Chronic Illness Symposium hosted by the Riordan Clinic. To find out more about the Riordan Clinic visit https://riordanclinic.org/
Lyme disease is a debilitating disease for many who contract it, and when traditional antibiotic therapy is only marginally effective or completely ineffective, little is currently offered these patients that can make a significant impact on improving the daily quality of their lives. The CDC currently estimates that there are 300,000 newly infected patients in the United States every year.
There remains a great deal of controversy whether some chronically ill Lyme patients have other ineffectively-treated pathogens keeping them ill, or whether these patients have somehow developed chronic degenerative diseases that have nothing to do with Lyme and Lyme-related pathogens but remained misdiagnosed as victims of Lyme disease. Nevertheless, it will be shown that Ascorbazone therapy is proving to be highly effective in both resolving clearly diagnosed Lyme cases while offering a great deal of improvement to the improperly diagnosed patient as well.
Ascorbazone therapy focuses on a goal of vitamin C (ascorbate) saturation throughout the body, with the addition of the potent anti-pathogen impact of properly-applied ozone-based therapies.
The presentation will discuss why Ascorbazone therapy is highly effective in curing, or at least clinically resolving, chronic Lyme patients, since Lyme antibodies can persist long after the infection has been resolved, allowing the academic argument of whether the infection is really gone to persist. Supporting scientific literature for the efficacy of ascorbate and ozone will be cited, and case reports will be presented and discussed as well.